The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain

被引：0
|
作者：
Christoph Springfeld
John P. Neoptolemos
机构：
[1] Heidelberg University Hospital,Department of Medical Oncology, National Center for Tumor Diseases
[2] Heidelberg University Hospital,Department of Surgery
来源：
Nature Reviews Clinical Oncology | 2022年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Patients with pancreatic ductal adenocarcinoma (PDAC) usually have a dismal prognosis, and even after curative resection most patients will have disease relapse and ultimately die. Nonetheless, adjuvant chemotherapy has considerably improved the outcomes of patients who are able to undergo surgery. The PREOPANC trial provides some evidence supporting the use of neoadjuvant therapy for patients with borderline resectable PDACs but not, as claimed, for those with resectable tumours.
引用
收藏
页码：285 / 286
页数：1
相关论文
共 50 条
  • [41] Neoadjuvant Chemoradiotherapy for Resectable and Borderline Resectable Pancreatic Cancer
    Attaallah, Wafi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 3346 - +
  • [42] Neoadjuvant Chemoradiotherapy for Resectable and Borderline Resectable Pancreatic Cancer
    Hayakawa, S.
    Karasawa, K.
    Fujisawa, T.
    Ito, K.
    Shibata, Y.
    Shimizuguchi, T.
    Nihei, K.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E236 - E236
  • [43] Neoadjuvant chemotherapy in resectable pancreatic cancer
    Irmscher, Sabrina
    Senninger, Norbert
    Schleicher, Christina
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (07) : 2059 - 2060
  • [44] Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer
    Sabrina Irmscher
    Norbert Senninger
    Christina Schleicher
    [J]. Annals of Surgical Oncology, 2008, 15 : 2059 - 2060
  • [45] Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer
    Daniel H. Palmer
    Deborah D. Stocken
    Helen Hewitt
    Catherine E. Markham
    A. Bassim Hassan
    Philip J. Johnson
    John A. C. Buckels
    Simon R. Bramhall
    [J]. Annals of Surgical Oncology, 2008, 15 : 2061 - 2061
  • [46] Neoadjuvant chemoradiotherapy for resectable pancreatic cancer
    Baker, Holly
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (05): : 392 - 392
  • [47] Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy
    Danko Mikulic
    Anna Mrzljak
    [J]. World Journal of Clinical Cases, 2021, 9 (20) : 5398 - 5407
  • [48] Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy
    Christians, Kathleen K.
    Heimler, Jonathan W.
    George, Ben
    Ritch, Paul S.
    Erickson, Beth A.
    Johnston, Fabian
    Tolat, Parag P.
    Foley, William D.
    Evans, Douglas B.
    Tsai, Susan
    [J]. SURGERY, 2016, 159 (03) : 893 - 900
  • [49] Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer
    Peng, June S.
    Wey, Jane
    Chalikonda, Sricharan
    Allende, Daniela S.
    Walsh, R. Matthew
    Morris-Stiff, Gareth
    [J]. HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2019, 18 (04) : 373 - 378
  • [50] Does neoadjuvant therapy improve survival in patients with resectable pancreatic cancer?
    Papalezova, K. T.
    Kim, V. M.
    Stinnett, S. S.
    Blazer, D. G., III
    Clary, B. M.
    Pappas, T. N.
    Tyler, D. S.
    White, R. R.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2010, 17 : S70 - S71
12345